Clinical Trial

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Study acronym: NUMANTIA
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 30, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2021-03-30; most recent amendment 2024-12-26.
Status change: Recruiting → Active, Not Recruiting 2023-12-27
Status change: Not Yet Recruiting → Recruiting 2021-10-04
Trial Details
NCT Number NCT04827953
Lead Sponsor Nelum Corp
Collaborators: Apices Soluciones S.L., Agenus Inc.
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 28 participants
Start Date 2021-09-01
Primary Completion 2025-04 (estimated)
Study Completion 2025-04 (estimated)
Updated on ClinicalTrials.gov 2024-12-30